Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a rabbit human glioblastoma model for testing of endovascular selective intra-arterial infusion (ESIA) of novel stem cell-based therapeutics.
Kan P, Srinivasan VM, Gumin J, Garcia R, Chen SR, Johnson JN, Collins DE, Chen MM, Ledbetter D, Huse J, Evan Luna ZA, Robledo A, Vasandani V, Rao A, Singh SK, Shpall EJ, Fueyo J, Gomez-Manzano C, Lang FF. Kan P, et al. Among authors: huse j. Neuro Oncol. 2024 Jan 5;26(1):127-136. doi: 10.1093/neuonc/noad152. Neuro Oncol. 2024. PMID: 37603323
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Butowski N, et al. Among authors: huse j. Neuro Oncol. 2016 Apr;18(4):557-64. doi: 10.1093/neuonc/nov245. Epub 2015 Oct 8. Neuro Oncol. 2016. PMID: 26449250 Free PMC article. Clinical Trial.
Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes.
Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T, Heimberger AB. Gabrusiewicz K, et al. Among authors: huse jt. Oncoimmunology. 2018 Jan 16;7(4):e1412909. doi: 10.1080/2162402X.2017.1412909. eCollection 2018. Oncoimmunology. 2018. PMID: 29632728 Free PMC article.
Effect of health disparities on overall survival of patients with glioblastoma.
Mandel JJ, Youssef M, Nam J, Patel AJ, Jalali A, Ludmir EB, Liu D, Wu J, Armstrong G, Huse J, Bondy M, de Groot JF. Mandel JJ, et al. Among authors: huse j. J Neurooncol. 2019 Apr;142(2):365-374. doi: 10.1007/s11060-019-03108-z. Epub 2019 Jan 22. J Neurooncol. 2019. PMID: 30671709
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. de Groot J, et al. Among authors: huse j. Neuro Oncol. 2020 Apr 15;22(4):539-549. doi: 10.1093/neuonc/noz185. Neuro Oncol. 2020. PMID: 31755915 Free PMC article.
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.
Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, Bdiwi M, Shaim H, Alsuliman A, Shanley M, de Groot JF, O'Brien BJ, Harrison R, Majd N, Kamiya-Matsuoka C, Fuller GN, Huse JT, Chi L, Rao G, Weinberg JS, Lang FF, Sawaya R, Shpall EJ, Rezvani K, Heimberger AB. Weathers SP, et al. Among authors: huse jt. Clin Cancer Res. 2020 Jul 15;26(14):3565-3577. doi: 10.1158/1078-0432.CCR-20-0176. Epub 2020 Apr 16. Clin Cancer Res. 2020. PMID: 32299815 Free PMC article. Clinical Trial.
Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration.
Ott M, Tomaszowski KH, Marisetty A, Kong LY, Wei J, Duna M, Blumberg K, Ji X, Jacobs C, Fuller GN, Langford LA, Huse JT, Long JP, Hu J, Li S, Weinberg JS, Prabhu SS, Sawaya R, Ferguson S, Rao G, Lang FF, Curran MA, Heimberger AB. Ott M, et al. Among authors: huse jt. JCI Insight. 2020 Sep 3;5(17):e134386. doi: 10.1172/jci.insight.134386. JCI Insight. 2020. PMID: 32721947 Free PMC article.
254 results